Scholar Rock Holding (SRRK) is back in focus after updating investors on an FDA warning letter sent to its manufacturing partner, Catalent Indiana, along with plans to resubmit its biologics license ...

This investor just walked away as Scholar Rock heads into a pivotal 2026—here’s what that means for long-term shareholders.

Scholar Rock Holding Corporation ( SRRK) Citi Annual Global Healthcare Conference 2025 December 3, 2025 1:00 PM EST ...

In early December 2025, Scholar Rock reported that reported that the Novo Nordisk Bloomington, Indiana site (formerly Catalent Indiana LLC) received an FDA warning letter, while the company still ...

CAMBRIDGE, Mass., November 18, 2025--(BUSINESS WIRE)--Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal ...

Scholar Rock (NASDAQ: SRRK), a global biopharmaceutical company dedicated to dramatically improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and ...

On Tuesday, 18 November 2025, Scholar Rock (NASDAQ:SRRK) presented at the Jefferies London Healthcare Conference 2025, discussing both challenges and strategic initiatives. The company addressed a ...

Scholar Rock Holding shares rose sharply Friday after the biopharmaceutical company gave a positive update on its efforts to win Food and Drug Administration approval of its proposed apitegromab ...

Investing.com - BMO Capital has raised its price target on Scholar Rock (NASDAQ:SRRK) to $50.00 from $45.00 while maintaining an Outperform rating on the stock.

Scholar Rock held a meeting with the FDA earlier this month to discuss the application. The third-party facility under question is undertaking remedies under new owners, Scholar Rock said. The company ...